Multiple adverse drug reactions and genetic polymorphism testing

Ana Lucía Arellano, Marta Martin-Subero, Mar Monerris, Adrián Llerena, Magí Farré, Eva Montané

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. Rationale: Defects in drug metabolic pathways could explain why some patients have a history of multiple adverse drug reactions (ADR); therefore we aimed to analyze genetic polymorphisms in a patient with multiple ADR related to drugs with a common hepatic metabolic pathway through CYP2D6. Patient concerns: We report a patient with psychosis and hypertension related to amitriptyline, tramadol, and duloxetine within a 2-year period. Interventions and Outcomes: A pharmacogenetic test was performed to assess the causative role of the CYP2D6 enzyme, but did not demonstrate a metabolic deficiency. Lessons: Although negative results in the reported case; typing for cytochrome P450 isoenzyme polymorphisms could be a useful diagnostic tool in some patients with a history of multiple ADR.
Original languageEnglish
Article numbere8505
JournalMedicine (United States)
Issue number45
Publication statusPublished - 1 Nov 2017


  • CYP2D6
  • adverse drug reactions
  • drug metabolism
  • genetic polymorphism
  • multiple drug intolerance syndrome


Dive into the research topics of 'Multiple adverse drug reactions and genetic polymorphism testing'. Together they form a unique fingerprint.

Cite this